Schonfeld Strategic Advisors LLC Purchases New Stake in Delcath Systems, Inc. (NASDAQ:DCTH)

Schonfeld Strategic Advisors LLC acquired a new position in shares of Delcath Systems, Inc. (NASDAQ:DCTH) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 50,225 shares of the company’s stock, valued at approximately $605,000. Schonfeld Strategic Advisors LLC owned 0.16% of Delcath Systems at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Jane Street Group LLC bought a new stake in shares of Delcath Systems during the 3rd quarter worth about $110,000. Barclays PLC acquired a new stake in Delcath Systems during the third quarter worth approximately $104,000. Baader Bank Aktiengesellschaft bought a new stake in shares of Delcath Systems during the fourth quarter worth approximately $204,000. Principal Financial Group Inc. grew its position in shares of Delcath Systems by 28.8% in the fourth quarter. Principal Financial Group Inc. now owns 115,183 shares of the company’s stock valued at $1,387,000 after purchasing an additional 25,736 shares during the last quarter. Finally, Private Advisor Group LLC bought a new position in shares of Delcath Systems during the fourth quarter worth approximately $153,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Craig Hallum upped their price objective on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Friday, January 17th. HC Wainwright boosted their target price on shares of Delcath Systems from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.75.

Delcath Systems Stock Performance

NASDAQ:DCTH opened at $14.84 on Friday. The company has a market cap of $496.15 million, a price-to-earnings ratio of -10.99 and a beta of 0.72. Delcath Systems, Inc. has a fifty-two week low of $5.30 and a fifty-two week high of $16.97. The stock has a fifty day moving average price of $12.31 and a 200-day moving average price of $12.57.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.07). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. Research analysts predict that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.